The stock of Deciphera Pharmaceuticals Inc (DCPH) has gone down by -5.51% for the week, with a -2.04% drop in the past month and a 5.58% rise in the past quarter. The volatility ratio for the week is 3.41%, and the volatility levels for the past 30 days are 4.06% for DCPH. The simple moving average for the past 20 days is -4.00% for DCPH’s stock, with a 4.39% simple moving average for the past 200 days.
Is It Worth Investing in Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) Right Now?
Company’s 36-month beta value is 0.41.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DCPH is 49.41M, and currently, short sellers hold a 12.26% ratio of that floaft. The average trading volume of DCPH on April 18, 2024 was 534.15K shares.
DCPH) stock’s latest price update
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) has experienced a decline in its stock price by -0.37 compared to its previous closing price of 14.72. However, the company has seen a fall of -5.51% in its stock price over the last five trading days. Zacks Investment Research reported 2024-03-07 that Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What’s next for the stock?
Analysts’ Opinion of DCPH
Many brokerage firms have already submitted their reports for DCPH stocks, with JP Morgan repeating the rating for DCPH by listing it as a “Neutral.” The predicted price for DCPH in the upcoming period, according to JP Morgan is $14 based on the research report published on November 20, 2023 of the previous year 2023.
Piper Sandler, on the other hand, stated in their research note that they expect to see DCPH reach a price target of $23. The rating they have provided for DCPH stocks is “Overweight” according to the report published on October 30th, 2023.
Stifel gave a rating of “Buy” to DCPH, setting the target price at $20 in the report published on August 10th of the previous year.
DCPH Trading at -6.27% from the 50-Day Moving Average
After a stumble in the market that brought DCPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -17.29% of loss for the given period.
Volatility was left at 4.06%, however, over the last 30 days, the volatility rate increased by 3.41%, as shares sank -7.59% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.85% lower at present.
During the last 5 trading sessions, DCPH fell by -6.22%, which changed the moving average for the period of 200-days by +3.67% in comparison to the 20-day moving average, which settled at $15.22. In addition, Deciphera Pharmaceuticals Inc saw -9.08% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DCPH starting from Kelly Thomas Patrick, who sale 3,010 shares at the price of $15.62 back on Feb 16 ’24. After this action, Kelly Thomas Patrick now owns 80,350 shares of Deciphera Pharmaceuticals Inc, valued at $47,009 using the latest closing price.
Sherman Matthew L, the EVP & Chief Medical Officer of Deciphera Pharmaceuticals Inc, sale 2,615 shares at $15.62 during a trade that took place back on Feb 16 ’24, which means that Sherman Matthew L is holding 108,739 shares at $40,840 based on the most recent closing price.
Stock Fundamentals for DCPH
Current profitability levels for the company are sitting at:
- -1.29 for the present operating margin
- 0.98 for the gross margin
The net margin for Deciphera Pharmaceuticals Inc stands at -1.19. The total capital return value is set at -0.57. Equity return is now at value -56.29, with -42.03 for asset returns.
Based on Deciphera Pharmaceuticals Inc (DCPH), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.67. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is 57.83.
Currently, EBITDA for the company is -208.86 million with net debt to EBITDA at 0.27. When we switch over and look at the enterprise to sales, we see a ratio of 6.89. The receivables turnover for the company is 5.11for trailing twelve months and the total asset turnover is 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.80.
Conclusion
In a nutshell, Deciphera Pharmaceuticals Inc (DCPH) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
